EUCTR2019-003218-15-PL进行中（未招募）1 期
A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasis - MODIFY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provide written informed consent prior to perform any study-related activity
- •2. Has completed the long-term extension of the reSURFACE 2 study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •1. Patients unable to comply with the requirements of the study
- •2. Patients who in the opinion of the investigator should not participate in the study
研究者
相似试验
招募中
3 期
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant studyRelapsed or refractory CD20 positive diffuse large B-cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12606000373572Roche40
进行中（未招募）
1 期
Study comparing Treatment with Alluzience vs Reconstituted toxin (STAR)Moderate to severe glabellar lines (GL).MedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858EUCTR2021-004748-62-DEQ-Med AB, part of the Galderma Group150
招募中
4 期
A prospective, phase IV study to check the effectiveness and safety of everolimus in liver transplant in Indian patientsCTRI/2018/07/014916ovartis India Limited
招募中
4 期
A clinical trial to evaluate aflibercept treatment in patients with diabetic macular edema.CTRI/2022/08/044792Bayer Zydus Pharma Private Limited
进行中（未招募）
4 期
To compare combination of study with marketed other combination of drug in patients having both anxiety and depression.CTRI/2022/11/047050Mankind Pharma Limited